Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial

About this Study

The purpose of this study is compare the good and bad effects of using Cabazitaxel with the usual approach of  the hormone based therapy Abiraterone Acteate in combination with Prednisone on patients with advance prostate cancer that have already undergone treatment with hormone therapy and docetaxel.

Sponsor Protocol ID:EA8153
IRB Number:2018-0192
Closed for Enrollment
Interventional
Early Phase 1
May 28, 2019
Eligibility Criteria
18 years old
Both Male and Female
Yes
No
No

Inclusion Criteria
  • Age ≥ 18 years
  • Sexually active males must use an accepted and effective method of double barrier contraception or abstain from
    sexual intercourse for the duration of their participation in
    the study and for 26 weeks after the last dose of study
    drug.

Exclusion Criteria
  • History of active malignancy.
  • Patients with a history of cancer that has been adequately treated and are free of disease recurrence for 3 years or more are allowed to participate.
  • Patients with a history of hypertension are allowed to enroll provided blood pressure is controlled with anti-hypertensive treatment.

Categories Click category to view its trials.
Cancer
Participating Locations
Cancer Center and Research Institute - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Jennifer Barnes
Phone Number: 601-815-4540
Email: jbarnes@umc.edu
Principal Investigator:Henegan, John C, M.D.
How to participate in our Clinical Trials